(Vax-Before-Travel News)<\/p>\n
While the European CDC says\u00a0Chikungunya is not endemic in mainland EU\/EEA, outbreaks<\/a>\u00a0have been reported in 2025.<\/p>\n According to the latest ECDC Communicable Disease Threats Report, as of August 6, 2025, France and Italy have reported locally acquired cases of chikungunya virus disease:<\/p>\n France’s\u00a0health authorities have identified 63 locally acquired cases of Chikungunya across 16 different local administrative units.<\/p>\n Currently, there are eleven active clusters. Notably, cases were reported for the first time in the Pyr\u00e9n\u00e9es-Atlantiques department, with three instances in one cluster. Additionally, three cases representing a new cluster were reported in Gard.<\/p>\n In the active clusters located in the departments of Corse-du-Sud, Is\u00e8re, H\u00e9rault, and Bouches-du-Rh\u00f4ne, two new cases have been reported in each cluster.<\/p>\n The most significant clusters are in southern France, specifically in Salon-de-Provence, Grans, and Lambesc in the Bouches-du-Rh\u00f4ne department, as well as Grosseto-Prugna in the Corse-du-Sud department, with each cluster consisting of 13 cases.<\/p>\n In Italy, two clusters remain active.<\/p>\n For the current risk assessment of chikungunya virus disease in mainland EU\/EEA, please visit the ECDC’s dedicated chikungunya webpage<\/a>.<\/p>\n Fortunately, chikungunya vaccines are approved for use in Europe and the United States.\u00a0<\/p>\n